title: Rapamycin impairs UV induction of mutant-p53 overexpressing cell clusters without affecting tumor onset.
abstract: Because of its antitumor effect, the immunosuppressant rapamycin holds great promise for organ transplant recipients in that it may lower their cancer risk. In a mouse model, we showed previously that rapamycin inhibits the outgrowth of primary skin carcinomas induced by UV radiation. However, the tumors that did grow out showed an altered p53 mutation spectrum. Here, we investigated whether this shift in p53 mutations already occurred in the smallest tumors, which were not affected in onset. We found that rapamycin did not alter the mutational spectrum in small tumors and in preceding microscopic clusters of cells expressing mutant-p53. However, rapamycin did reduce the number of these cell clusters. As this reduction did not affect tumor onset, we subsequently investigated whether rapamycin merely suppressed expression of mutated p53. This was not the case, as we could demonstrate that switching from a diet with rapamycin to one without, or vice versa, did not affect the number of existing mutant-p53 expressing cell clusters. Hence, rapamycin actually reduced the formation of mutant-p53 cell clusters. In wild-type and p53-mutant mice, we could not measure a significant enhancement of UV-induced apoptosis, but we did observe clear enhancement in human skin equivalents. This was associated with a clear suppression of HIF1α accumulation. Thus, we conclude that rapamycin reduces the formation of mutant-p53-expressing cell clusters without affecting tumor onset, suggesting that tumors grow out of a minor subset of cell clusters, the formation of which is not affected by rapamycin.
authors.affiliation: Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands. p.voskamp@gmail.com
authors.forename: P
authors.initials: P
authors.lastname: Voskamp
authors.forename: C A
authors.initials: CA
authors.lastname: Bodmann
authors.forename: H G
authors.initials: HG
authors.lastname: Rebel
authors.forename: G E
authors.initials: GE
authors.lastname: Koehl
authors.forename: C P
authors.initials: CP
authors.lastname: Tensen
authors.forename: J N
authors.initials: JN
authors.lastname: Bouwes Bavinck
authors.forename: A
authors.initials: A
authors.lastname: El Ghalbzouri
authors.forename: H J
authors.initials: HJ
authors.lastname: Van Kranen
authors.forename: R
authors.initials: R
authors.lastname: Willemze
authors.forename: E K
authors.initials: EK
authors.lastname: Geissler
authors.forename: F R
authors.initials: FR
authors.lastname: De Gruijl
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000032:analysis; D016158:Genes, p53; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors; D051379:Mice; D008812:Mice, Hairless; D009154:Mutation; D009381:Neoplasms, Radiation-Induced / Q000235:genetics / Q000517:prevention & control*; D020123:Sirolimus / Q000494:pharmacology*; D014466:Ultraviolet Rays
chemical_list: D000903:Antibiotics, Antineoplastic; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D053148:Caspase 3; D020123:Sirolimus